Effects of 12 mg vs. 6 mg dexamethasone on thromboembolism and bleeding in patients with critical COVID-19 - a post hoc analysis of the randomized, blinded COVID STEROID 2 trial

Annals of Intensive Care

Table 3 Risk of death or thromboembolism, thromboembolism, major bleeding, and any bleeding by dose of dexamethasone

Characteristic	OR	95% CI	p-value
Death or thromboembolism, unadjusted	0.98	0.62 to 1.54	0.92
Death or thromboembolism, adjusted^a	0.93	0.58 to 1.49	0.77
Thromboembolism, unadjusted	0.98	0.49 to 1.96	0.96
Thromboembolism, adjusted^a	0.97	0.48 to 1.94	0.93
Major bleeding, unadjusted	0.98	0.39 to 2.45	0.97
Major bleeding, adjusted^a	0.97	0.39 to 2.42	0.94
Any bleeding, unadjusted	0.80	0.48 to 1.33	0.39
Any bleeding, adjusted^a	0.78	0.46 to 1.30	0.34

Odds ratios for death or thromboembolism, thromboembolism, major bleeding and any bleeding during ICU stay among 357 patients with critical COVID-19 with 12 mg vs. 6 mg dexamethasone daily
OR odds ratio, CI confidence interval
^aAdjusted for age (< / ≥ 70 years) and invasive mechanical ventilation (yes/no)